JP2005517412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005517412A5 JP2005517412A5 JP2003568094A JP2003568094A JP2005517412A5 JP 2005517412 A5 JP2005517412 A5 JP 2005517412A5 JP 2003568094 A JP2003568094 A JP 2003568094A JP 2003568094 A JP2003568094 A JP 2003568094A JP 2005517412 A5 JP2005517412 A5 JP 2005517412A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antisense oligonucleotide
- nephropathy
- activity
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35637402P | 2002-02-12 | 2002-02-12 | |
| PCT/US2003/004186 WO2003068983A1 (en) | 2002-02-12 | 2003-02-12 | Use of the axl receptor for diagnosis and treatment of renal disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005517412A JP2005517412A (ja) | 2005-06-16 |
| JP2005517412A5 true JP2005517412A5 (https=) | 2006-04-13 |
Family
ID=27734638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003568094A Pending JP2005517412A (ja) | 2002-02-12 | 2003-02-12 | 腎疾患の診断及び治療のためのＡｘｌ受容体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20030157573A1 (https=) |
| EP (1) | EP1483400A4 (https=) |
| JP (1) | JP2005517412A (https=) |
| CN (1) | CN1646695A (https=) |
| AU (1) | AU2003223172A1 (https=) |
| IL (1) | IL163547A0 (https=) |
| WO (1) | WO2003068983A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003223172A1 (en) * | 2002-02-12 | 2003-09-04 | Quark Biotech, Inc. | Use of the axl receptor for diagnosis and treatment of renal disease |
| AU2003286746A1 (en) * | 2002-10-29 | 2004-05-25 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| EP1732650A4 (en) | 2004-03-27 | 2008-06-11 | Univ Arizona | COMPOSITION AND METHOD FOR CANCER TREATMENT |
| TW200726845A (en) * | 2006-01-02 | 2007-07-16 | Nat Defense Medical Ct | Biomarker molecular of renal illness and detecting method for the same |
| EP2079736B1 (en) | 2006-12-29 | 2017-10-18 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| WO2009005813A1 (en) * | 2007-07-02 | 2009-01-08 | Wyeth | Modulators of axl for use in treating bone disorders |
| US9074192B2 (en) | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| CA2786149C (en) | 2010-01-22 | 2019-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl signaling in anti-metastatic therapy |
| WO2013090776A1 (en) * | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| RS55728B1 (sr) | 2012-01-31 | 2017-07-31 | Daiichi Sankyo Co Ltd | Derivat piridona |
| EP2626705A1 (en) * | 2012-02-13 | 2013-08-14 | Institut d'Investigacions Biomédiques August Pi i Sunyer | Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome |
| JP6992960B2 (ja) * | 2013-12-02 | 2022-02-03 | ベルゲンビオ アーエスアー | キナーゼ阻害剤の用途 |
| CA2965153C (en) * | 2014-10-20 | 2023-10-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US10137173B2 (en) | 2014-10-20 | 2018-11-27 | Aravive Biologics, Inc. | Antiviral activity of Gas6 inhibitor |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| EP4063853A1 (en) | 2017-01-12 | 2022-09-28 | Astute Medical, Inc. | Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement |
| ES2977788T3 (es) | 2017-04-20 | 2024-08-30 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco |
| CN113215157B (zh) * | 2021-05-20 | 2022-06-21 | 徐州医科大学 | 特异性靶向人AXL基因的sgRNA及其应用 |
| CN113252911B (zh) * | 2021-07-02 | 2021-12-10 | 珠海丽珠试剂股份有限公司 | SARS-CoV-2中和抗体的检测试剂盒及其应用 |
| KR102763266B1 (ko) * | 2021-11-30 | 2025-02-04 | 충남대학교산학협력단 | Axl을 포함하는 지방간 예방 또는 치료용 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468634A (en) * | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
| AU697142B2 (en) * | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
| AU1518595A (en) * | 1994-01-14 | 1995-08-01 | Genentech Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
| US5538861A (en) * | 1994-07-29 | 1996-07-23 | Amgen Inc. | DNA encoding a stimulating factor for the axl receptor |
| US6211142B1 (en) * | 1995-03-10 | 2001-04-03 | Genentech, Inc. | Compositions comprising gas6 polypeptides and articles of manufacture comprising the same |
| US5849585A (en) * | 1995-05-10 | 1998-12-15 | Genetech, Inc. | Isolating and culturing Schwann cells |
| US20040102389A1 (en) * | 1995-10-26 | 2004-05-27 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| US6235769B1 (en) * | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
| US6236769B1 (en) * | 1998-01-28 | 2001-05-22 | Cognex Corporation | Machine vision systems and methods for morphological transformation of an image with zero or other uniform offsets |
| US20030149113A1 (en) * | 2001-10-12 | 2003-08-07 | Caplan Michael J. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20020165158A1 (en) * | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| EP1575976A4 (en) * | 2001-11-02 | 2006-08-23 | Insert Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE |
| AU2003223172A1 (en) * | 2002-02-12 | 2003-09-04 | Quark Biotech, Inc. | Use of the axl receptor for diagnosis and treatment of renal disease |
| US20030229906A1 (en) * | 2002-04-15 | 2003-12-11 | Gelman Irwin H. | Methods and compositions for the treatment of disorders of HIV infection |
| DE602004028587D1 (de) * | 2003-01-16 | 2010-09-23 | Univ Pennsylvania | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1 |
-
2003
- 2003-02-12 AU AU2003223172A patent/AU2003223172A1/en not_active Abandoned
- 2003-02-12 IL IL16354703A patent/IL163547A0/xx unknown
- 2003-02-12 JP JP2003568094A patent/JP2005517412A/ja active Pending
- 2003-02-12 CN CNA038082365A patent/CN1646695A/zh active Pending
- 2003-02-12 US US10/365,135 patent/US20030157573A1/en not_active Abandoned
- 2003-02-12 WO PCT/US2003/004186 patent/WO2003068983A1/en not_active Ceased
- 2003-02-12 EP EP03719300A patent/EP1483400A4/en not_active Withdrawn
-
2007
- 2007-07-10 US US11/827,198 patent/US20090075923A1/en not_active Abandoned
-
2008
- 2008-01-07 US US12/006,999 patent/US20090042826A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005517412A5 (https=) | ||
| JP2023058575A5 (https=) | ||
| JP2014511686A5 (https=) | ||
| JP2021531022A5 (https=) | ||
| JP2006500958A5 (https=) | ||
| JP2020058368A5 (https=) | ||
| JP2017536119A5 (https=) | ||
| JP2012050438A5 (https=) | ||
| JP2012029693A5 (https=) | ||
| JP2010533171A5 (https=) | ||
| JP2020022483A5 (https=) | ||
| EP1723162A4 (en) | ANTI-microRNA oligonucleotide molecules | |
| JP2005517430A5 (https=) | ||
| WO2007134014A3 (en) | Compounds and methods for modulating expression of gcgr | |
| JP2008513513A5 (https=) | ||
| EP1799859A4 (en) | IMPROVED ANTISENSE OLIGONUCLEOTIDE | |
| EP1941908A4 (en) | THERAPEUTIC AGENT AGAINST HEART DISEASES | |
| JP2012105686A5 (https=) | ||
| JP2009544281A5 (https=) | ||
| JP2006502243A5 (https=) | ||
| JP2013537404A5 (https=) | ||
| WO2006117400A3 (en) | Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors | |
| JP2007517498A5 (https=) | ||
| JP2005517783A5 (https=) | ||
| JP2006510659A5 (https=) |